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Skeletal  muscle  adapts  its mass  as consequence  of physical  activity,  metabolism  and  hormones.  Catabolic
conditions  or  inactivity  induce  signaling  pathways  that  regulate  the  process  of muscle  loss.  Muscle  atro-
phy  in  adult  tissue  occurs  when  protein  degradation  rates  exceed  protein  synthesis.  Two  major  protein
degradation  pathways,  the  ubiquitin-proteasome  and  the autophagy-lysosome  systems,  are  activated
during  muscle  atrophy  and  variably  contribute  to the  loss of muscle  mass.  These  degradation  systems  are
controlled  by  a  transcription  dependent  program  that  modulates  the  expression  of rate-limiting  enzymesbiquitin protesaome
oxO
uscle wasting
of  these  proteolytic  systems.  The  transcription  factors  FoxO,  which  are  negatively  regulated  by  Insulin-
Akt  pathway,  and  NF-B,  which  is  activated  by inﬂammatory  cytokines,  were  the  ﬁrst  to be identiﬁed  as
critical  for  the  atrophy  process.  In the  last  years  a variety  of pathways  and  transcription  factors  have  been
found  to be involved  in  regulation  of atrophy.  This  review  will  focus  on the last  progress  in  ubiquitin-
proteasome  and  autophagy-lysosome  systems  and  their  involvement  in  muscle  atrophy.  This article  is
part of  a Directed  Issue  entitled:  Molecular  basis  of muscle  wasting.© 2013 The Author. Published by Elsevier Ltd. 
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. Introduction occurs during development, in response to mechanical overload
Open access under CC BY license.Skeletal muscle mass and muscle ﬁber size may  vary accord-
ng to physiological and pathological conditions. An increase in
uscle mass and ﬁber size, i.e. muscle growth or hypertrophy,
 This article is part of a Directed Issue entitled: Molecular basis of muscle
asting.
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357-2725 © 2013 The Author. Published by Elsevier Ltd. 
ttp://dx.doi.org/10.1016/j.biocel.2013.04.023
Open access under CC BY license.and/or anabolic hormonal stimulation. During development, the
growth of skeletal muscle, like the mass of any other tissue, depends
on protein and cellular turnover. In adulthood, the regulation of
muscle mass and ﬁber size essentially reﬂects protein turnover,
namely the balance between protein synthesis and degradation
within the muscle ﬁbers. Muscle atrophy involves the shrinkage of
myoﬁbers due to a net loss of proteins, organelles and cytoplasm.
Acute muscle atrophy, as occurs in many pathological conditions, is
due to hyperactivation of the cellular main degradation pathways,
including the ubiquitin-proteasome system and the autophagy-
lysosome pathways. Recent studies have highlighted a complex
scenario whereby these catabolic signaling modulate one another
at different levels, and are also connected at various levels to
biosynthetic pathways (Bonaldo and Sandri, 2013). The result is
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 coordinated balance between protein degradation and synthe-
is that reﬂects the physiological state of the muscle ﬁber. Before
onsidering mechanisms of muscle atrophy, it is useful to make
ome general considerations:
1) A transcriptional dependent upregulation of the atrophy-
related gene at mRNA level does not always match with an
increase of protein level. The ﬁeld of muscle wasting should
consider the fact that transcriptional-dependent induction of
several atrophy related genes is required to replenish the
enzymes/proteins that are lost during the enhanced protein
breakdown. Importantly, the muscle-speciﬁc atrophy-related
ubiquitin ligases atrogin1/MAFbx and MuRF1 similarly to
other E3s, undergo auto-ubiquitination (Bodine et al., 2001).
It is reasonable that an increased ligase activity of these
E3s during inactivity or catabolic conditions would inevitably
amplify their auto ubiquitination action, thus resulting in
increased proteasomal-dependent degradation. Therefore, the
transcriptional upregulation is particularly important mostly to
replenish the loss of the ubiquitin ligase protein that occurs as
a consequence of the increased activity. This concept should
be considered when protein expression does not match with
transcript induction. In autophagy-lysosome system, the
proteins LC3, p62 and BNIP3 are critical for membrane
commitment, cargo delivery and selective removal of dam-
aged mitochondria, respectively. To elicit their functions
these proteins are entrapped into the autophagosome when
the vesicle is formed and therefore, are destroyed upon
fusion of autophagosome with lysosome. The transcrip-
tional dependent upregulation of these genes is important
to maintain their level during an enhancement of autophagy
ﬂux.
2) A decrease of protein synthesis can not be considered alone
as the mechanism of atrophy. The size of a postmitotic cell
results from the balance between protein synthesis and degra-
dation. Indeed, in condition of protein synthesis inhibition the
total protein content of the cell is affected by protein’ half-life
that depends on basal protein breakdown. Therefore, paradox-
ically in situations of decreased protein synthesis the cell size
ultimately depends more on protein breakdown than in cir-
cumstances of normal protein synthesis.
3) A decrease of nuclear turnover or of the satellite cell pool
can not explain muscle atrophy in adulthood.The myonu-
clear domain is not constant in various conditions including
growth and atrophy. Recent evidences underlie that myonu-
clear turnover is negligible in adulthood after postnatal growth
(White et al., 2010). Moreover, no myonuclear addition has
been shown in different models of muscle hypertrophy and
depletion of satellite cells does not prevent muscle hyper-
trophy (Amthor et al., 2009; Blaauw et al., 2009; Jackson
et al., 2012; Lee et al., 2012; Raffaello et al., 2010). In addi-
tion, reduction of Pax7 positive cells in adult muscles is
not sufﬁcient to trigger muscle wasting in normal condi-
tion (McCarthy et al., 2011). These recent ﬁndings together
with the concept that during muscle atrophy the myonuclear
domain decreases suggest that lack of satellite cell prolifer-
ation and fusion is not the major contributor of the atrophy
process.
. Muscle atrophyMuscle atrophy involves the shrinkage of myoﬁbers due to
 net loss of proteins, organelles and cytoplasm. The ubiquitin-
roteasome system and the autophagy-lysosome pathway are the
egradation systems involved in this process.istry & Cell Biology 45 (2013) 2121– 2129
2.1. The autophagy-lysosome system
From the discovery that FoxO transcription factors coordinate
the activation of the ubiquitin proteasome and of autophagy-
lysosome pathways in atrophying muscles (Sandri, 2010), a great
interest emerged for autophagy and many studies have underlined
the induction of this system in different pathological conditions
of muscle wasting. A detailed description of the different types
of autophagy, including their regulation and involvement in mus-
cle homeostasis has been recently reviewed (Bonaldo and Sandri,
2013). Brieﬂy, autophagy is a highly conserved homeostatic mecha-
nism used for the degradation and recycling, through the lysosomal
machinery, of bulk cytoplasm, long-lived proteins and organelles
(Mizushima and Komatsu, 2011). Although autophagy was  initially
considered a non-selective degradation pathway, the presence of
more selective forms of autophagy is becoming increasingly evi-
dent. Indeed, autophagy can trigger the selective removal of speciﬁc
organelles, such as mitochondria via mitophagy or protein aggre-
gates.
Several years ago autophagy-lysosome system was  described
to be activated in muscle cells during catabolic conditions (Bechet
et al., 2005; Deval et al., 2001; Tassa et al., 2003). However,
the interest on this pathway emerged recently in the muscle
community. During the last few years autophagy has been found
to be modulated in muscle by a plethora of situations including
cancer (Penna et al., 2013), ageing (Penna et al., 2013; Wenz et al.,
2009; Wohlgemuth et al., 2010), fasting (Mammucari et al., 2007;
Mizushima et al., 2004), caloric restriction (Grumati et al., 2010;
Wohlgemuth et al., 2010), sepsis (Mofarrahi et al., 2012), critically
illness (Derde et al., 2012), cirrhosis (Qiu et al., 2012), chemio-
therapy (Smuder et al., 2011), disuse (Brocca et al., 2012) and
denervation (O’Leary et al., 2012a; Zhao et al., 2007). Importantly,
autophagy is physiologically induced by exercise including both
endurance and resistance exercise and mediates the metabolic
beneﬁcial effects of physical activity on glucose homeostasis
(Grumati et al., 2011; He et al., 2012; Jamart et al., 2012a,b; Luo
et al., 2013). We  were the ﬁrst to discover that autophagy is acti-
vated by endurance exercise (Grumati et al., 2011) and this effect
have been recently conﬁrmed on humans (Jamart et al., 2012a,b).
The rationale of exercise-dependent autophagy activation is still
unclear but evidences suggest that autophagy is important for
removal of proteins/organelles that are damaged by exercise itself
or is a mechanism to provide energy for sustained contraction.
These two hypotheses need to be better deﬁned soon. For instance,
the initial observation that autophagy is critical for glucose homeo-
stasis has been recently challenged. In fact, opposite results have
been recently published related to the role of autophagy on insulin
sensitivity in skeletal muscle. Indeed both activation or inhibition
of autophagy have been reported to ameliorate glucose uptake
and lipids metabolism in diet-induced obesity (He et al., 2012;
Kim et al., 2013). The two  studies have used different transgenic
mice that may  account for the different results. The initial study
had used transgenic mice that contain knock-in mutations in BCL2
phosphorylation sites that prevent stimulus-induced disruption
of the BCL2-beclin-1 complex and autophagy activation (He et al.,
2012). These mice are characterized by a normal autophagy ﬂux
that cannot be increased by fasting or exercise. BCL2 mutant mice,
which express this mutant protein in every tissue, show decreased
endurance and altered glucose metabolism during acute exercise,
as well as impaired chronic exercise-mediated protection against
high-fat-diet-induced glucose intolerance. In this study the cell
autonomous issue was  never addressed therefore, we  do not have
any idea how and which tissue contributes to the beneﬁcial effect
on sugar homeostasis. The second study used a muscle-speciﬁc
Atg7 knockout mice in which autophagy is selectively blocked in
skeletal muscle. These animals showed decreased fat mass and
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ere protected from high fed diet (HFD) induced obesity and
nsulin resistance (Kim et al., 2013). The amelioration of insulin
ensitivity is due to a mitochondrial-dependent signal. In fact
itochondrial dysfunction induced by autophagy deﬁciency stim-
lated Fgf21 expression through activation of Atf4, a transcription
actor activated by the Unfolded Protein Response pathway.
gf21 is released from muscle and its inhibition attenuates the
eneﬁcial effects on glucose tolerance and insulin sensitivity
f muscle-speciﬁc autophagy knockout during diet-induced
besity.
Mitochondria regulation is important to preserve muscle func-
ion and for the regulation of general metabolism and indeed,
his organelle changes morphology and number as consequence of
uscle activity. The mitochondrial network can be remodeled by
he fusion/ﬁssion proteins, the mitochondrial shaping machinery,
nd by the selective removal of small mitochondria via autophagy,
 process named mitophagy (Romanello and Sandri, 2012) (Fig. 1).
n mammals, parkin, PINK1, Bnip3 and Bnip3L have been shown
o regulate mitophagy, and inactivation of the genes coding for
hese proteins leads to mitochondrial abnormalities (Bothe et al.,
000; Hara et al., 2006). PINK1 is normally absent in healthy
itochondria because it is constitutively degraded by mitochon-
rial proteases. However, once mitochondria are damaged, PINK1 is
o longer degraded and accumulates. Moreover, PINK1 is also under
ranscriptional control of FoxO family (Fig. 1) PINK1 induces parkin
ecruitment to mitochondria, promoting mitophagy through ubi-
uitination of outer mitochondrial membrane proteins that are rec-
gnized by p62, which then brings autophagic vesicles to ubiquit-
nated mitochondrial proteins (Narendra and Youle, 2011; Youle
nd Narendra, 2011). Parkin also ubiquitinates mitofusins promot-
ng their degradation via proteasome (Sarraf et al., 2013; Ziviani
t al., 2010). This action is important to prevent mitochondrial
usion and to facilitate mitochondrial fragmentation and removal
ia mitophagy. Bnip3 and Bnip3L are BH3-only proteins localized
t the outer membrane of the mitochondria after cellular stress,
nd bind directly to LC3, thereby recruiting the autophagosome
o damaged mitochondria (Hanna et al., 2012; Novak et al., 2010).
n atrophying muscle, the mitochondrial network is dramatically
emodeled following fasting or denervation, and autophagy via
nip3 contributes to mitochondrial changes (Mofarrahi et al., 2012;
’Leary et al., 2012b; Romanello et al., 2010; Romanello and Sandri,
010). Expression of the ﬁssion machinery is sufﬁcient to cause
uscle wasting in mice, whereas inhibition of mitochondrial ﬁssion
revents muscle loss during denervation, indicating that disruption
f the mitochondrial network is a crucial ampliﬁcatory loop of the
uscle atrophy program (Romanello et al., 2010; Romanello and
andri, 2010). Conversely, impairment of basal mitophagy leads to
he accumulation of damaged and dysfunctional mitochondria that
ontribute to myoﬁber degeneration (Grumati et al., 2010). There-
ore autophagy is critical to maintain myoﬁber function by clearing
bnormal organelles. Accordingly, the phenotype of mice with
uscle-speciﬁc inactivation of various genes coding for autophagy-
elated proteins, such as Atg7, Atg5 or nutrient-deprivation
utophagy factor-1 (NAF-1), a Bcl-2 associated autophagy regula-
or, results in atrophy, weakness and different myopathic features
Chang et al., 2012; Masiero et al., 2009; Raben et al., 2008). In
ddition, altered regulation of autophagy-related genes leads to
uscle dysfunction. Histone deacetylases 1 and 2 (HDACs) were
ound to regulate muscle autophagy by controlling the expression
f autophagy genes. Muscle-speciﬁc ablation of both HDAC1 and
DAC2 results in partial perinatal lethality, while those HDAC1/2
nockout mice that survive develop a progressive myopathy char-
cterized by impaired autophagy (Moresi et al., 2010, 2012).
Despite the important advancement in signaling pathways that
ontrol the autophagy machinery, the precise functions, in vivo,
f the core autophagy components in membrane commitment,istry & Cell Biology 45 (2013) 2121– 2129 2123
growth and fusion to form an autophagosome as well as in the
docking of autophagosome to lysosome and in the fusion into
an autophagolysosome are largely unknown. One of the most
important regulatory element is the beclin1/Vps34/Vps15 com-
plex. Vps34 is a Class III phosphatidylinositol 3-kinase (PI3K)
enzyme that generates PI3-phosphate from PI, while Vps15 is
a regulatory subunit that is required for Vps34 activity. There-
fore, Vps34 and Vps15 are obligate partners that form the core
for the association of different proteins to generate distinct com-
plexes that regulate autophagosome biogenesis and endosome
trafﬁcking. The beclin1/Vps34/Vps15/Atg14L complex is required
for autophagosome biogenesis and indeed drugs that block Vps34
activity prevents autophagosome formation in cell culture. The role
of Vps15 in adult muscle has been recently investigated by a loss of
function approach. Surprisingly, muscle-speciﬁc Vps15 knockout
mice showed normal LC3 lipidation and autophagosome forma-
tion but impaired autophagosome lysosome fusion (Nemazanyy
et al., 2013). Importantly, deletion of Vps15 results in almost dis-
appearance of Vps34 and beclin1 proteins suggesting that these
proteins are unstable when they do not interact to form a com-
plex. Therefore, the ﬁrst important ﬁnding is that in adult tissue
the PI3K complex is not required for the correct function of the
autophagy conjugation system and for autophagosome biogen-
esis but its action is more relevant in autophagosome docking
and fusion with lysosomes (Fig. 1). The second important ﬁnd-
ing is related to muscle phenotype. In fact Vps15 knockout mice
showed myopathic features including buildup of autophagosomes,
abnormal glycogen accumulation, anomalous lysosomes, necrotic
cell death, regenerating myoﬁber and elevated creatine kinase
plasma levels. These characteristics are reminiscent of Autophagic
Vacuolar Myopathy. Importantly, overexpression of Vps15 and
Vps34 reactivates autophagy and cleared glycogen accumulation
in myotubes obtained from Danon patient, a lysosomal storage
disease characterized by glycogen buildup. These ﬁndings, accord-
ingly to recent data on Pompe patients (Nascimbeni et al., 2012a,b),
suggest that autophagy impairment is the major pathogenetic
mechanism that contributes to muscle wasting in lysosome stor-
age disorders and that autophagy reactivation is beneﬁcial and
not detrimental for myoﬁber function. This concept is further
supported by the ﬁrst genetic disease casued by a mutation in
an autophagy-related gene, the Vici syndrome. Vici syndrome
is a recessive inherited multisystem disorder characterised by
cardiomyopathy, callosa agenesis, cataracts, and combined immu-
nodeﬁciency. Interestingly, skeletal muscle of Vici patients display
consistent myopathic features, including atrophy of type 1 ﬁbers,
centrally nucleated ﬁbers and abnormal glycogen accumulation
(Cullup et al., 2013). Electron microscopy analyses of myoﬁbers
revealed the presence of exocytic vacuoles, numerous vacuole-
like area and dense bodies that resemble lysosomes and abnormal
mitochondria. The genetic defect has been identiﬁed in muta-
tions of EPG5 gene, which encodes for a protein predominantly
expressed in cardiac and skeletal muscle, central nervous system,
thymus, immune cells, lung and kidney. Importantly, the C. elegans
homolog of EPG-5 plays a critical role in the autophagy process
(Tian et al., 2010) (Fig. 1). In agreement with worms, myoﬁbers
and ﬁbroblast of Vici patients display accumulation of p62, Nbr1
and lipidated LC3, thus conﬁrming that the autophagy system is
blocked (Cullup et al., 2013). The presence of LC3/p62 and Nbr1/p62
double positive puncta, as well as the reduction of colocalization
between LC3 and LAMP-1, suggest that the fusion of autophago-
some with lysosome is blocked in these patients (Cullup et al.,
2013). These data have been conﬁrmed by the phenotype of EPG-
5 knockout mice. Deletion of EPG-5 leads to selective damage of
cortical layer 5 pyramidal neurons and spinal cord motor neurons
resulting in muscle degeneration, myoﬁber atrophy, and reduced
survival (Zhao et al., 2013). Interestingly, morphological studies of
2124 M. Sandri / The International Journal of Biochemistry & Cell Biology 45 (2013) 2121– 2129
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aig. 1. Signaling modules responsible for autophagy-lysosome pathway in the adu
f  mitochondria, autophagosome docking and fusion with lysosome and new lysos
ines  point to mechanisms that are not yet known.
astrocnemius muscle showed centrally nucleated and vacuo-
ated ﬁbers, while ultrastructural analyses revealed misalignment
f Z-lines and accumulation of abnormal enlarged mitochonria
esembling the features of Atg7 deﬁcient muscle. Consistently with
ici patients, autophagy ﬂux is blocked in gastrocnemius muscle of
PG-5 knockout mice. An interesting observation is that deletion
f EPG-5 leads to abnormalities in endosome trafﬁcking and recep-
or recycling. Therefore, Vici syndrome is the ﬁrst multisystemic
isorder associated with defective autophagy. The role of EPG5 in
he autophagy pathway and the crass talk between autophagy and
ndocityc system are two important points that need to be explored
n the future.
.2. The ubiquitin-proteasome
In the ubiquitin-proteasome system, proteins are targeted for
egradation by the 26S proteasome through covalent attachment
f a chain of ubiquitin molecules. The ubiquitin ligase enzyme,
r E3, binds the protein substrate and catalyzes the movement
f the ubiquitin from the E2 enzyme to the substrate. This is the
ate-limiting step of the ubiquitination process, which affects the
ubsequent proteasome-dependent degradation. Once the protein
s ubiquitinated it is docked to the proteasome for degradation,
nless the polyubiquitin chain is removed by the de-ubiquitinating
nzymes. Among the different E3s, only a few have been found
o regulate atrophy process and to be transcriptionally induced in
trophying muscle.
The ﬁrst to be identiﬁed were Atrogin-1/MAFbx and MuRF1.
hese two E3s are speciﬁcally expressed in striated and smooth
uscles (Bdolah et al., 2007; Bodine et al., 2001; Gomes et al., 2001).
trogin-1/MAFbx and MuRF1 knockout mice are resistant to mus-
le atrophy induced by denervation (Bodine et al., 2001). MuRF1
nockout mice are also resistant to dexamethasone-induced mus-
le atrophy (Baehr et al., 2011) while, knockdown of atrogin-1
pare muscle mass in fasted animals (Cong et al., 2011). Thus far,
uRF1 ubiquitinates several muscle structural proteins, including
roponin I (Kedar et al., 2004), myosin heavy chains (Clarke et al.,
007; Fielitz et al., 2007), actin (Polge et al., 2011), myosin bind-
ng protein C and myosin light chains 1 and 2 (Cohen et al., 2009).
hereas the substrates of atrogin-1 that have been identiﬁed seem
o be involved in growth-related processes or survival pathways.
trogin-1 promotes degradation of MyoD, a key muscle transcrip-
ion factor, and of eIF3-f, an important activator of protein synthesis
Csibi et al., 2010; Tintignac et al., 2005). In the heart, atrogin-1
biquitinates and reduces the levels of calcineurin A, an impor-
ant factor triggering cardiac hypertrophy in response to pressure
verload (Li et al., 2004). However a recent work, have found that
trogin-1 interacts with sarcomeric proteins, including myosins,
esmin, and vimentin, as well as transcription factors, components
f the translational machinery, enzymes involved in glycolysis
nd gluconeogenesis and mitochondrial proteins (Lokireddy et al.,e different modules are: autophagosome formation, selective autophagic removal
ormation. Each module is controlled by different pathways and factors. The dotted
2012a). Whether this interaction results in ubiquitination of these
proteins has yet to be proven.
Since two ubiqutin ligases cannot effort for the degradation of
all the sarcomeric and soluble proteins, additional E3s are involved
in muscle loss. Speciﬁc ubiquitin-ligases may  be involved in
different models of muscle wasting and at different stages of the
atrophy process. For instance, the HECT domain ubiquitin ligase
Nedd4-1 has been reported to be upregulated mainly during
disuse. Indeed deletion of the Nedd4-1 gene speciﬁcally in skele-
tal muscle results in partial protection from muscle atrophy in
denervated type II ﬁbers. However, Nedd4-1 knockout mice have
smaller muscles, suggesting that this E3 may  play additional roles
during myogenesis or in the control of protein synthesis (Nagpal
et al., 2012). Recently, Trim32 has been reported to degrade
thin ﬁlaments (actin, tropomyosin and troponins), -actinin and
desmin (Cohen et al., 2012). However, Trim32 knockout mice
are not protected from atrophy, but instead show an impaired
recovery of muscle mass after atrophy (Kudryashova et al., 2012).
Another E3 ubiquitin ligase found to play a critical role in atro-
phy is TRAF6 (Paul et al., 2010), which mediates the conjugation of
Lys63-linked polyubiquitin chains to target proteins. Lys48-linked
polyubiquitin chains are a signal for proteasome-dependent degra-
dation, but Lys63-linked polyubiquitin chains play other roles, such
as regulating autophagy-dependent cargo recognition by interac-
ting with the scaffold protein p62 (also known as SQSTM1) (Kirkin
et al., 2009; Komatsu et al., 2007; Pankiv et al., 2007). Notably,
muscle-speciﬁc TRAF6 knockout mice have a decreased amount
of polyubiquitinated proteins, almost no Lys63-polyubiquitinated
proteins in starved muscles (Paul et al., 2012) and are resistant to
muscle loss induced by denervation, cancer or starvation (Kumar
et al., 2012; Paul et al., 2010, 2012). The mechanism of this protec-
tion involves both direct and indirect effects of TRAF6 on protein
breakdown. Inhibition of TRAF6 reduces the induction of atrogin-
1 and MuRF1, thereby preserving muscle mass under catabolic
conditions. Moreover, TRAF6-mediated ubiquitination may  have
additional function on modulating intracellular signaling. In fact
TRAF6 is required for the optimal activation of JNK, AMPK, FoxO3
and NF-B pathways (Paul et al., 2012). The effects on FoxO3 and
NF-B may  explain why atrogin-1 and MuRF1 are less induced in
TRFAF 6 knockout mice.
Mul1 is a mitochondrial ubiquitin ligase that plays an important
role in mitochondrial network remodeling. Mul1 is upregulated
in catabolic conditions, such as fasting or denervation, by the
FoxO family of transcription factors and causes mitochondrial frag-
mentation and removal via autophagy (Lokireddy et al., 2012b).
Importantly, knocking down Mul1 spares muscle mass during
fasting. It is unclear whether such protection occurs in other
models of muscle wasting such as denervation. Mul1 ubiquiti-
nates the mitochondrial pro-fusion protein mitofusin 2, causing
its degradation via the proteasome system. The exact mecha-
nism that triggers Mul1-dependent mitochondrial dysfunction and
ochem
m
d
(
l
f
a
p
ﬁ
w
H
a
s
t
A
t
d
f
t
e
i
r
h
m
i
a
t
p
t
u
a
d
a
u
c
i
b
e
a
s
i
2
p
c
i
o
i
K
d
h
2
t
i
t
a
d
a
p
iM. Sandri / The International Journal of Bi
itophagy is unclear (Fig. 1), but it has been reported that mitofusin
egradation is permissive for mitochondrial ﬁssion and mitophagy
Romanello et al., 2010).
Another ligase is CHIP, which regulates ubiquitination and
ysosomal-dependent degradation of ﬁlamin C, a muscle protein
ound in the Z-line (Arndt et al., 2010). Filamins undergo unfolding
nd refolding cycles during muscle contraction and are therefore
rone to irreversible damage (Arndt et al., 2010). Alterations to
lamin structure triggers the binding of the co-chaperone BAG3,
hich carries a complex made up of the chaperones Hsc70 and
spB8, as well as the ubiquitin ligase CHIP. CHIP ubiquitinates BAG3
nd ﬁlamin, which are recognized and delivered to the autophagy
ystem by p62 (Arndt et al., 2010). Interestingly, ﬁlamin B is con-
rolled, at least during myogenesis, by another ubiquitin ligase,
SB2, which is mainly expressed in muscle cells. In this case,
he ubiquitination of ﬁlamin B by ASB2 leads to proteasome-
ependent degradation (Bello et al., 2009).
In skeletal muscle, E3 ligases also have important regulatory
unctions in signaling pathways. For example, it was  recently found
hat the ubiquitin ligase Fbxo40 regulates anabolic signals (Shi
t al., 2011). Fbxo40 ubiquitinates and affects the degradation of
nsulin receptor substrate 1 (IRS1), a downstream effector of insulin
eceptor-mediated signaling. Inhibition of Fbxo40 by RNAi induces
ypertrophy in myotubes, and Fbxo40 knockout mice display bigger
uscle ﬁbers (Shi et al., 2011).
Although some E3 ligases involved in muscle protein ubiquit-
nation and breakdown have been identiﬁed, very little is known
bout how ubiquitinated proteins are recognized and delivered
o the proteasome. ZNF216 has been identiﬁed as an important
layer in the recognition and delivery of ubiquitinated proteins to
he proteasome during muscle atrophy. Interestingly, ZNF216 is
pregulated by FoxO transcription factors in atrophying muscles,
nd ZNF216-deﬁcient mice are partially resistant to muscle loss
uring denervation. The absence of ZNF216 in muscle leads to the
ccumulation of polyubiquitinated proteins (Hishiya et al., 2006).
Another important system for extraction and degradation of
biquitinated proteins from larger structures is the p97/VCP ATPase
omplex. P97/VCP is induced during denervation, and overexpress-
on of a dominant negative p97/VCP reduces overall proteolysis
y the proteasome and lysosome pathways, and blocks the accel-
rated protein breakdown induced by FoxO3. Interestingly, p97
nd its cofactors, Ufd1 and p47, have been found associated with
peciﬁc myoﬁbrillar proteins, suggesting a role for p97 in extract-
ng ubiquitinated proteins from myoﬁbrils (Piccirillo and Goldberg,
012).
While a great body of research has focused on the ubiquitination
rocess, little is known about the role of deubiquitination, and its
ontribution to muscle atrophy. The largest class of deubiquitinat-
ng enzymes (DUBs) are ubiquitin-speciﬁc proteases (USPs). So far,
nly two (USP14 and USP19) have been found to be upregulated
n atrophying muscles (Combaret et al., 2005; Gomes et al., 2001).
nocking down USP19 in myotubes results in decreased protein
egradation and reverts dexamethasone-induced loss of myosin
eavy chain (Sundaram et al., 2009).
.3. Proteolysis-dependent regulation of protein synthesis and
herapeutic application
Synthesis and degradation of proteins are two  processes that are
ntimately connected. Indeed, most of the above mentioned sys-
ems are regulated by pathways that impinge on both synthesis
nd degradation, so that when protein synthesis is induced degra-
ation is suppressed and vice versa (Fig. 2). This control seems to be
 compensatory mechanism to limit the energy expenditure for the
roduction of novel proteins during catabolic conditions. However,
n certain situations protein synthesis is increased during muscleistry & Cell Biology 45 (2013) 2121– 2129 2125
atrophy. For instance, in denervated muscles net protein synthesis
is increased rather than decreased compared to innervated mus-
cles (Quy et al., 2012). This is because a portion of the amino
acids released from protein breakdown stimulate protein synthe-
sis via mTOR, and if this mechanism is blocked, then muscle loss is
exacerbated (Quy et al., 2012). The direct action of amino acids on
translation plays an important role in the production and activation
of stress response pathways, changing metabolism and expression
of sarcomeric proteins in order to optimize muscle homeostasis and
performance to the new condition. An important example of amino
acid-dependent regulation of gene transcription during a catabolic
state has recently been described for lysosomal-dependent protein
degradation. Nutrients, especially free amino acids, are sensed by
the mTOR kinase, which then inhibits autophagy by blocking the
formation of the Atg1/ULK1 complex, an important regulatory step
for autophagy initiation. The mTORC1 complex is therefore at the
center of a variety of cellular process such as protein synthesis,
autophagy, ageing, mitochondrial function and energy production.
These different actions of mTORC1 are exploited by its localiza-
tion/recruitment to different cellular compartments. For instance,
the Rag GTPase complex, which senses lysosomal amino acids,
promotes the localization of mTORC1 at the lysosomal surface.
Accumulation of amino acids within the lysosomal lumen generates
an activating signal that is transmitted to the Rag GTPases via the
vacuolar H+-adenosine triphosphatase ATPase (v-ATPase) recruit-
ing mTORC1 to the lysosomes. This mTOR localization initiates the
amino acid signaling and protein synthesis (Zoncu et al., 2011). Con-
comitantly, mTOR also inhibits the Transcription Factor EB (TFEB),
a master regulator of lysosome biogenesis (Settembre et al., 2011).
Activation of mTORC1 induces phosphorylation and localization of
TFEB at the lysosomal membrane, thus inhibiting its transcriptional
activity (Settembre et al., 2012). These data indicate that con-
tent/activity of the lysosome directly regulates lysosome biogenesis
via an mTOR-TFEB axis. The implication of this signaling as it relates
speciﬁcally to muscle homeostasis has yet to be investigated.
The mechanisms controlling muscle mass have attracted
increasing interest in the scientiﬁc community due to their poten-
tial to address various clinical problems, such as aging, the
prognosis of many diseases, quality of life and sports medicine. The
results of recent research offer new and exciting perspectives to
the ﬁeld, that will hopefully identify new therapeutic targets and
drugs.
Several potentially interesting therapeutic targets have already
been identiﬁed, although an effective drug that can counteract mus-
cle wasting is not yet clinically available. The most interesting
targets belong to the anabolic pathways and the ubiquitin-
proteasome system. The Akt signaling and its downstream targets
seem to be at the intersection of several different pathways, includ-
ing -adrenergic signaling, myostatin and JunB. Moreover, the
IGF1-Akt axis is unique in that it controls both protein synthe-
sis and protein degradation. Therefore, IGF-1 analogs might be
extremely useful for counteracting muscle loss and weakness.
However, the same pathway plays major roles in other biologi-
cal processes, including cell survival, and in other contexts it can
promote tumorigenesis. Thus, the development of a new genera-
tion of IGF1 mimetics that speciﬁcally activate the Akt pathway in
skeletal muscle is a goal for the ﬁeld. It is important to underline
that prolonged inhibition of protein degradation can have a major
impact on protein quality control and muscle performance. Such
agents could have major drawbacks, such as promoting the accu-
mulation of misfolded or aggregate-prone proteins (Grumati et al.,
2010; Masiero et al., 2009).Recent data identiﬁed SGK1 as an important inhibitor of FoxOs
and of muscle atrophy. By studying the mechanisms that protect
squirrel from muscle wasting during hibernation it was found that
SGK1 and not Akt was the critical factor that blocked FoxO activity
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Iig. 2. Signaling modules that are important therapeutic targets to counteract mu
kt-mTOR-FoxO module. The dotted lines point to pathways that are not yet dissec
nd muscle atrophy (Andres-Mateos et al., 2013). The fact that
GK1 controls phosphorylation sites of FoxO that are overlapping
ith those under Akt regulation, is a well establish concept that
as been neglected in the last years (Brunet et al., 2001; Calnan
nd Brunet, 2008). The role of SGK1 must be considered when
kt phosphorylation does not ﬁt with muscle phenotype and
ith FoxO phosphorylation. Moreover, SGK1 might be a better
herapeutic target than Akt, since its action is more important in
reventing muscle atrophy than promoting muscle growth.
In fact promoting protein synthesis without acting on pro-
ein breakdown may  be not sufﬁcient to prevent muscle atrophy
nd weakness. Indeed in a recent study it was analyzed the role
f TSC1 in muscle growth and atrophy by generating muscle-
peciﬁc TSC1 knockout mice. These animals showed an activation
f TORC1 pathway and an increase of protein synthesis but surpris-
ngly, glycolytic muscles were atrophic due to an hyperactivation
f FoxO3-dependent atrophy program (Bentzinger et al., 2013).
herefore, just increasing protein synthesis is not sufﬁcient to coun-
eract an enhancement of protein breakdown when an atrophy
rogram is induced.
An alternative approach would consider the development of
rugs that activate negative modulators of FoxO transcription
actors such as JunB (Raffaello et al., 2010), or PGC-1 (Sandri et al.,
006). FoxOs have been found to interact with PGC-1,  a critical
ofactor for mitochondrial biogenesis (Puigserver et al., 2003; Wu
t al., 1999). Maintaining high levels of PGC-1 during catabolic
onditions (either in transgenic mice or by transfecting adult
yoﬁbers) spares muscle mass during denervation, fasting, heart
ailure, aging and sarcopenia (Geng et al., 2011; Sandri et al., 2006;
enz et al., 2009). Similar beneﬁcial effects were recently obtained
y overexpression of PGC-1,  a homologue of PGC-1 (Brault et al.,
010). The positive action on muscle mass of these cofactors is due
o the inhibition of autophagy-lysosome and ubiquitin-proteasome
egradation. PGC-1  and PGC-1 reduce protein breakdown by
nhibiting the transcriptional activity of FoxO3 and NF-B, but they
o not affect protein synthesis (Brault et al., 2010). Thus, these
ofactors prevent the excessive activation of proteolytic systems by
nhibiting the action of the pro-atrophy transcription factors with-
ut perturbing the translational machinery. However, a novel form
f PGC-1  (PGC-14), which results from alternative promoter
sage and splicing of the primary transcript, has been recently
ound to be involved in muscle growth, as shown by the ﬁnding
hat mice with skeletal muscle-speciﬁc transgenic expression of
GC-14 show increased muscle mass and strength (Ruas et al.,
012). PGC-14, which is expressed at signiﬁcant levels in skeletal
uscle, is a shorter, truncated form of the previously described
GC-1, now referred to as PGC-11. PGC-14 was found to induce
GF1 and repress myostatin, thus promoting hypertrophy and
educing muscle atrophy during cancer or hindlimb suspension.
nterestingly, also JunB markedly suppresses myostatin expressionasting. Most of the pathways converge onto a ﬁnal common pathway centered on
in transfected myotubes and decreases the phosphorylation of
Smad3, the transcription factor downstream of the myostatin-
TGF signaling pathway (Raffaello et al., 2010). JunB can block
myoﬁber atrophy of denervated tibialis anterior muscles and cul-
tured myotubes induced by FoxO3 overexpression, dexamethasone
treatment or starvation. In these conditions, JunB prevents the
activation of atrogin-1 and partially of MuRF-1, thereby reducing
the increase in overall protein degradation induced by activated
FoxO3. Further analysis revealed that JunB does not inhibit FoxO3-
mediated activation of the autophagy-lysosome system, but
only ubiquitin-proteasome degradation, by inhibiting atrogin-1
and MuRF-1 induction during catabolic conditions. In fact, JunB
directly binds FoxO3, thereby preventing its recruitment to the
promoters of key atrogenes. Moreover, JunB overexpression is
sufﬁcient to induce dramatic hypertrophy of myotubes and of adult
muscle. These hypertrophic changes depend on increased protein
synthesis, without affecting the basal rate of protein degradation.
Recently the hormone ghrelin was found to prevent muscle
wasting (Porporato et al., 2013). Ghrelin is a peptide hormone
that stimulates growth hormone (GH) release and positive energy
balance through binding to the receptor GHSR-1a. Only acylated
ghrelin (AG), but not the unacylated form (UnAG), can bind GHSR-
1a; however, UnAG and AG share several GHSR-1a-independent
biological activities. Both AG and UnAG inhibited dexamethasone-
induced skeletal muscle atrophy and atrogenes expression.
Upregulation of circulating UnAG in mice impaired skeletal muscle
atrophy induced by either fasting or denervation without stim-
ulating muscle hypertrophy and GHSR-1a-mediated activation
of the GH/IGF-1 axis. Importantly, both AG and UnAG seems to
activate Akt independently of the receptor GHSR-1a and therefore
are acting on an unidentiﬁed receptor. Besides the therapeutic
properties of AG/UnAG the identiﬁcation of their receptor in mus-
cle is an important issue for developing novel and more speciﬁc
drugs.
Beta-adrenergic agonists such as clenbuterol are considered
pro-growth and anti-atrophic drugs. Most effects of clenbuterol are
mediated by activating Akt-mTOR signaling (Kline et al., 2007), so
the concerns associated with IGF1 stimulation can also be applied to
-adrenergic agonists. However a recent report revealed that the
-adrenergic signal might act via a different mechanism (involv-
ing a G protein coupled receptor and Gi2 induceing hypertrophy
through inhibition of GSK-3 and activation of p70S6K1) that is
independent of the PI3K-Akt axis (Minetti et al., 2011). Notably, the
contribution of p70S6K1 and its downstream target S6 to protein
synthesis in muscle is uncertain, as S6K1 knockout mice show no
impairment of polysome formation, protein synthesis or protein
degradation (Mieulet et al., 2007). Therefore, S6 phosphorylation
should not be considered a marker of protein synthesis, and we
need a better understanding of which mTOR downstream targets
are crucial regulators of protein synthesis in order to evaluate the
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ole of this pathway in muscle growth and its potential in thera-
eutic approaches.
The last category of drug targets is represented by the pro-
easome system. Proteasome inhibitors have been successfully
sed to block atrophy in different animal models (Caron et al.,
011; Jamart et al., 2011; Supinski et al., 2009). However, the
biquitin-proteasome system regulates many relevant biological
rocesses and its prolonged inhibition might be detrimental for
uscle cells. Indeed, patients chronically treated with bortezomib,
 proteasome inhibitor that was approved by FDA to treat multi-
le myeloma, display cardiac complications (Enrico et al., 2007).
herefore, more speciﬁc approaches that can target the ubiquitin
igases involved in ubiquitination and degradation of sarcomeric
roteins should be pursued. Among the different ubiquitin ligases,
uRF1 and TRAF6 seem interesting candidates for developing spe-
iﬁc inhibitors. However, ablation of MuRF1 or TRAF6 only partially
rotects from muscle loss during denervation in mice (Bodine et al.,
001; Paul et al., 2010), indicating that other ubiquitin ligases are
lso involved in protein degradation. Moreover, it is still unknown
hether different muscle atrophic conditions recruit different sets
f ubiquitin ligases. Nonetheless, the ﬁndings of these last few years
ave greatly enhanced our knowledge of protein synthesis and
egradation in skeletal muscle, and there is increasing hope that
t will be possible to develop efﬁcient therapeutic approaches for
ounteracting muscle wasting in the near future.
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